DiscoverMedical News PodcastEvolving Second-Line Strategies in HER2+ Lung Cancer
Evolving Second-Line Strategies in HER2+ Lung Cancer

Evolving Second-Line Strategies in HER2+ Lung Cancer

Update: 2025-11-03
Share

Description

Drs. Rotow and Cooper explore the evolving landscape of HER2+ NSCLC treatment, highlighting recent advancements in targeted therapies like HER2 TKIs and antibody-drug conjugates. They emphasize the importance of comprehensive biomarker testing, the significance of personalized treatment approaches, and the exciting progress in providing more effective and tolerable second-line therapies for patients. The discussion underscores the field's movement toward precision medicine and the potential for future combination strategies and improved patient outcomes.
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Evolving Second-Line Strategies in HER2+ Lung Cancer

Evolving Second-Line Strategies in HER2+ Lung Cancer

PeerDirect Publishing